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Functional recovery from fragility fractures such as those of the lower limb, hip or spine in 
older people with frailty is often limited. Patients often have pre-fracture muscle weakness, 
which worsens due to the injury, and both pain and general ill health interfere with 
resistance exercise which is the mainstay of motor recovery. One possible adjunct to 
rehabilitation in such people is neuromuscular electrical stimulation (NMES), which can 
stimulate muscles while the patient is resting. The feasibility of NMES in older people with 
fragility fractures has not previously been determined, nor is it yet clear whether such 
patients require additional protein supplementation to benefit from NMES. We present a 




Participants will be patients in hospital with reduced mobility due to fragility fractures of 
the spine, pelvis, hip or lower limb. A randomised controlled feasibility trial will be 
conducted in which participants will be randomised either to have the left or right leg 
stimulated using NMES and therefore using the non-stimulated leg as a control, and also 
randomised either to have or not have an oral protein supplement during treatment 
sessions. NMES sessions will be daily until discharge from hospital to a maximum of 6 
weeks. Outcomes will include measures of efficacy of NMES at the muscular impairment 
level (strength, muscle ultrasound parameters, intramuscular electromyographic 
parameters), feasibility outcomes (recruitment and retention rates, compliance and 




This study is a necessary step before NMES can be included in a multimodal intervention 
package to optimise recovery after fragility fracture. 
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Extensions in human longevity in western countries since industrial times have not only led 
to longer periods of life spent in good health, but have also been associated with 
increasing periods of time spent in poor health at the end of life. The average UK man and 
woman, with life expectancies of 79 and 83 respectively, spend around 13 and 19 years 
respectively at the end of life in poor health [1]. It would be desirable to minimise the 
amount of time spent in poor health - for the health span to be closer to the lifespan. 
Muscular weakness leading to loss of function is a major contributor to poor health in these 
years towards the end of life [2]. The loss of muscle strength, quality and mass seen with 
advancing age is “sarcopenia”. Sarcopenia is one of the most important deficits associated 
with frailty – the vulnerability state seen with ageing that leads to, and is associated with, 
disability and other health problems. Sarcopenia, like other age-associated changes, is a 
consequence of genetic factors interplaying with numerous known and unknown 
environmental and behavioural factors. Regular exercise is protective against the 
development of sarcopenia. Being sedentary also, and additionally, contributes to 
sarcopenia. Intervention studies show that resistance exercise training at least partly 
reverses sarcopenia, even in extreme old age.  
The muscle protein synthetic response to resistance exercise is reliant upon adequate 
amount of habitual dietary protein intake. The average western adult diet has 
approximately twice the amount of protein specified in dietary guidelines [3], and protein 
deficiency in clinical practice is generally associated with severe protein malabsorption or 
protein losing conditions. Guidelines for protein requirements for older people are generally 
higher than for younger adults (in terms of grams of protein per kilogram body weight). 
This is because of “anabolic blunting”, the age-associated reduction in the ability to 
synthesise muscle protein in response to a given protein load and exercise challenge [4]. 
However, guidelines do not currently advise specific protein supplementation as a 
treatment to prevent or reverse sarcopenia. 
Sarcopenia in hospitalised patients 
Many older people, especially those with frailty and hence existing sarcopenia, are 
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fracture of the hip, spine, pelvis, or leg after a fall, but almost any medical illness in an 
older person with frailty can lead to a loss of function such that they become immobile. 
The period of immobility after such conditions depends upon the prior function and 
strength of the individual, the amount of pain, general health issues and access to 
rehabilitation, and can vary from a day, to several weeks. Occasionally the loss of mobility 
can be permanent. Periods of immobility, whatever the cause, lead to further loss of 
muscle mass and strength – disuse atrophy [5]. This process may be even more rapid in 
hospitalised patients due to the effects of inflammation and illness, which may depress 
muscle metabolism further. Furthermore, if immobility is for extended periods and energy 
intake remains unchanged then disuse atrophy leads to whole-body and muscle fat mass 
gain, both of which are associated with poor health outcomes. Patients will not return to 
prior levels of physical function and body composition unless they reverse these 
immobility-induced changes and, some will never become mobile again.  
Usual clinical care on geriatric and orthopaedic wards is to mobilise such patients as soon 
as possible, to keep them mobilised, to avoid bed rest to reduce the amount of sedentary 
behaviour, and to optimise their diets. Patients who are not mobile are advised to do chair 
based or seated exercises. The limited evidence about the benefit of such exercises 
suggests that they are of little value [6]. Part of the reason for this is that they are difficult 
to perform in adequate intensity when patients are ill, tired, or in pain. These same factors 
may reduce appetite. However, in line with the current evidence-base and consensus 
opinions, clinical teams do not routinely offer nutritional supplements to all older immobile 
patients, but reserve them for those who do not consume a diet that meets recommended 
dietary guidelines.  
Possible approaches to improving outcome 
A review of approaches to loss of muscle function in hospitalised patients identified several 
potential therapeutic options beyond resistance exercise and optimal diet: drug therapy 
(e.g. anabolic steroids, growth hormone), neuromuscular electrical stimulation, and oral 
protein supplementation [7]. This review showed that there is promising evidence that 
each of these interventions could improve outcomes, but the evidence is insufficient for 
any of them to apply them routinely in clinical practice. However, there is sufficient 
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This study  
In this study, we aim to evaluate the effect of neuromuscular electrical stimulation as an 
addition to best care in people admitted to hospital who have reduced mobility due to a 
fragility fracture. Given concerns that the potential benefits of this treatment may be 
limited by dietary protein intake, we will study this with and without a high protein oral 
nutritional supplement. We have chosen not to study drug therapy as well: safety concerns 
will limit the applicability and desirability of this mode of treatment, whereas 
neuromuscular stimulation, with protein supplementation if required, is likely to be suitable 
for widespread use.  
Neuromuscular electrical stimulation  
The variant of neuromuscular electrical stimulation we will test involves a small electric 
current applied via a pad applied to the skin overlying the nerves supplying the muscles of 
the leg while the patient is lying in bed. A trained operator applies treatment to one leg, 
for approximately 30 minutes per session, three sessions per week. The electrical current 
goes through the pad and skin and stimulates the underlying nerves, which in turn 
stimulate the muscles supplied by those nerves to contract and thus then stimulates 
muscle growth and the associated metabolic responses that prevent loss of muscle. 
Treatment can stimulate the nerve controlling the vastus lateralis muscle in the thigh or 
the nerve controlling the tibialis anterior muscle in the lower leg, or both. In our study, we 
will aim to stimulate both nerves and muscle groups, on the basis that the maximal effect 
with result from the maximal amount of muscle stimulated. One of our feasibility questions 
will be to determine the degree to which we can achieve this aim. The stimulation may 
also stimulate the central nervous system (spine and brain via afferent pathways) and 
create adaptive change in these tissues as well, and these effects may reduce pain and 
hence have a bearing on the ease with which patients can perform exercise (pain will be a 
secondary outcome). However, the main mechanism responsible for beneficial effects on 
strength is at the level of the muscle. Stimulation via the nerve recruits a larger amount of 
muscle than other forms of stimulation such as those applied over the muscle itself: this is 
important because the greater the amount of muscle stimulated the more likely we will 
achieve a meaningful clinical effect. It is usual to start sessions with small electrical 
currents initially and to ramp this up gradually within a session - this develops tolerance to 
the initial uncomfortable sensations that some patients can experience. Treatment is 
adjusted to generate a specific force and maintained for up to 5 minutes, followed by a 
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stimulation can vary according to the frequency (pulses per second, typically 10-50Hz). 
Pulses vary in width and intensity and these parameters can affect both comfort and the 
amount of muscular activation achieved: wider pulse widths tend to be the most 
comfortable. Over-stimulation can lead to fatigue, a loss of force resulting from stimulation 
greater than that needed to achieve beneficial adaptation. We will adjust the level of 
stimulation to the level of muscle force generated by the target muscle. We will reassess 
this at regular intervals to account for adaptation to the stimulation. There is no 
recognised optimal specific set of these parameters that optimises contraction and comfort 
and avoids fatigue, which is why we will individualise these parameters in each individual.  
Neuromuscular electrical stimulation is widely advertised as a treatment modality used in 
physiotherapeutic practice in people of a wide range of ages and conditions, and in 
athletes [9]. This indicates that it is generally a safe technique although avoided in 
pregnancy for precautionary reasons, in those with implanted electrical devices to avoid 
interference, and where there are moist skin lesions or wounds where the skin pad is to be 
applied. The evidence for its effectiveness from controlled studies, particularly in older 
people with frailty, is limited. There have been promising studies conducted in 
oropharyngeal dysphagia and foot drop after stroke, in the sarcopenia (loss of muscle) 
associated with COPD and kidney failure, in osteoarthritis of the knee and after elective 
knee and hip surgery. The lack of large-scale studies with clinical outcomes means that 
widespread adoption of the technique and optimisation of the potential health gain from it 
is not yet justifiable [9].            
We propose to use neuromuscular electrical stimulation during initial periods of immobility 
in older people after a fracture, and to continue it during the periods of bed rest until the 
patient is discharged, or for a maximum of 6 weeks (representing the main recovery 
period). Although neuromuscular electrical stimulation could play a valuable role in the 
development or maintenance of further rehabilitation gains, this would require a different, 
longer-term, study. This is why we are not extending the intervention phase beyond 
discharge in this study. 
In this study, we will stimulate one of the participants’ legs, using the other leg as a 
control comparison. Allocation of which leg is stimulated with be on a randomised basis to 
avoid allocation biases and will ensure that we will apply NMES to legs affected by injury as 
well as those without - as would be anticipated in usual, bilateral clinical practice. Whilst in 
a clinical efficacy study we would aim to stimulate both legs, in this study our outcomes 
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appropriately by single leg stimulation. Our primary efficacy measures in this study are at 
the single limb level – later trials (if justified) will have primary outcomes relevant to 
bilateral stimulation such as gait speed and disability. 
Additional protein supplementation: high protein supplement   
Neuromuscular electrical stimulation alone (in the presence of usual nutritional support) 
may be sufficient to improve outcome, and studies to date in community dwelling patients 
have not required additional protein supplementation. However, many older patients in 
hospital consume an inadequate diet. Our audits have shown that patients with hip 
fractures consume about 1/3 of their daily requirement of calories and less than ½ their 
daily requirement of protein [8]. Protein is required around the time of exercise so that 
amino-acids (the building blocks of proteins) are circulating in the blood stream ready to 
be incorporated into muscle protein during the hour or two after exercise. If there are 
inadequate levels of amino acids either because not enough protein is being consumed or 
if it is being used to provide energy (i.e. as calories) then neuromuscular electrical 
stimulation could fail to improve muscle function. We propose to overcome this potential 
problem by offering single doses of a high protein supplement after each bout of 
neuromuscular electrical stimulation. We appreciate that this does not solve the general 
problem of under-nutrition in hospital, and that much more research and development is 
required to solve that issue. However, by studying the effect of neuromuscular electrical 
stimulation with and without additional protein, we will establish whether future trials of 
neuromuscular electrical stimulation need to include protein supplementation as a 
necessary part of the overall treatment. We will randomly allocate participants offering half 
of them additional protein supplementation over and above their ordinary diet. In this way, 
we will be able to observe the effect at the muscle level of neuromuscular stimulation (a 
comparison between legs), and its effect with and without additional protein 
supplementation (on a randomised basis). Oral Nutritional Supplements (ONS), which are 
widely used within the acute and community health settings for individuals who are unable 
to meet their nutritional requirements through oral diet alone. A single (100g) portion of 
high protein supplement gives approximately 20g protein. 
 
Purpose, aim and objectives 
The overall purpose of this research is to contribute to minimising the impact of frailty by 
reducing muscle weakness. The aim of this study is to determine whether it is justifiable to 
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additional protein supplementation in hospitalised patients who are temporarily 
immobilised following a fragility fracture. The objectives of the study are  
 1. to determine the proportion of patients with fragility fractures who will consent to 
this study, and their characteristics  
2. to determine the compliance with and acceptability of neuromuscular electrical  
stimulation treatment and participant characteristics affecting this 
3. to determine the compliance with and acceptability of protein supplementation and 
participant characteristics affecting this 
4. to determine the short term effect of neuromuscular electrical stimulation with or 
without additional protein supplementation upon measures of neuromuscular function and 
structure, and the effect of compliance with treatment upon these measures   
5. to determine recruitment parameters and suitable outcome measures for a 
subsequent RCT with clinical outcomes  
 
METHOD 
Study setting  
The study will be performed at hospital trauma and geriatric medical wards in Nottingham 
University Hospitals NHS Trust. 
Study Participants  
Inclusion criteria:  
• >/=65 years  
• Hospitalised due to incident fragility fracture (hip, spine, pelvis, rib, upper limb, lower limb) 
• New mobility status as a consequence of the fracture  
• Not expected to be discharge within 7 days of recruitment    
Exclusion criteria:  
Subjects will be excluded from this proposed study if they are: 
• Unable to give valid informed consent (later work may explore the option of 
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• Resident outside catchment area of hospital (likely to be moved during the study 
period)   
• Unable to communicate in English sufficiently to participate in neuromuscular 
electrical stimulation  
• Implanted medical device (e.g. pacemaker) 
• Any other contraindications to neuromuscular electrical stimulation (e.g. injury to 
all stimulation sites) 
• Leg amputation or any pre-injury conditions affecting a leg unilaterally such as 
hemiparesis 
• Dysphagia for liquids 
• End stage renal failure (dialysis) 
• Obesity (BMI>30) 
• End of life, for any reason 
• Any other clinical reason why rehabilitation is not clinically indicated 
 
Study design 
This study is Feasibility RCT. A parallel group RCT design and will be conducted over a 
period of 15 months. We will offer all recruited participants neuromuscular electrical 
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Figure 1. Study design flow chart 
 
Sample size: 
Our proposed total sample size is 60 participants. Sample size calculations are typically not 
required for many feasibility study outcomes where statistical testing is not required. 
Sample sizes of 20 are usually sufficient to estimate recruitment rates and examine the 
suitability of outcome measures.  
 
Participant identification and screening 
Potential participants will be identified from hospital fracture registers and from hospital 
trauma and geriatric medical wards by Clinical Research Network (CRN) staff. The CRN 
staff will apply the eligibility criteria as far as possible by consulting their medical records, 
their attending health care professionals. They will keep an anonymised screening log of 
potential participants, recording the date of screening, place of screening and hospital 
number of all participants with eligible fractures (to avoid repeated screening of potential 





This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported 
License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc- nd/3.0/ . 
15//04/2015 V1 
 
ISSN: 2059-3341  





Research staff will approach potential participants identified as above, and re-apply the 
eligibility criteria. Written consent will be required. After the collection of baseline data, 
consenting participants will be randomly allocated, using the online “Sealed Envelope” 
randomisation service, to one of four equal groups (NMES = neuromuscular electrical 
stimulation):  
• NMES left leg, no high protein supplementation 
• NMES left leg, high protein supplementation 
• NMES right leg, no high protein supplementation 
• NMES right leg, high protein supplementation 
 
Measurements 
There is no single, primary endpoint, but several outcomes of interest: 
• Recruitment rate: We will calculate this by comparing the number of recruits to 
those identified by the screening logs and examine their characteristics by 
examining the exclusion criteria. 
• Number of treatment sessions, duration of treatment sessions, period over which 
treatment sessions are delivered, maximal intensity of stimulation during treatment 
sessions, proportion of participants stimulated in thigh / lower leg / both, reasons 
for missing sessions:  This will serve to determine the compliance with and 
acceptability of neuromuscular electrical stimulation treatment and participant 
characteristics affecting this. 
• Number of protein supplementation doses consumed and acceptability 
questionnaire of NMES: This is to determine the compliance with and acceptability 
of NMES and participants’ characteristics affecting this. At the end of each session, 
the patients will be asked to complete a short verbal questionnaire. They will be 
asked: If they would consider NMES as an acceptable treatment for lower limb 
weakness after a period of immobilisation. 
• Tolerability questionnaire: At the end of each session, the patients will be asked to 
complete a short verbal questionnaire. They will be asked: to give a verbal 
categorical rating of the NMES treatment, as: ‘very comfortable’, ‘comfortable’, 
‘bearable’ or ‘unbearable’. If they noticed a difference in the sensation due to 
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• Ultrasound parameters: Using a portable bedside device to determine the short-
term effect of neuromuscular electrical stimulation (thickness, pennation angle, 
echogenicity). Ultrasound is well tolerated. Conducting gel is applied to the skin and 
the scanner is pressed against the muscle and moved until good images are 
obtained. The whole process will take 20 minutes.  
• Intramuscular electromyography(iEMG): Intramuscular electromyography (iEMG) is 
another measure of the potential effect of neuromuscular electrical stimulation. We 
will perform intramuscular electromyography (iEMG), in both legs, at the first 
treatment session and the last treatment session to determine the change in these 
variables. The whole process will take 20 minutes.      
• A hand-held dynamometer:  is a portable measurement device to assess Lower 
limb muscle strength.  
• Elderly Mobility Scale: This is a simple 20-point measure of mobility which is widely 
used to assess the overall mobility in frail older people [9].We will apply the Elderly 
Mobility Scale in the last treatment session before discharge.  
• Hand grip strength: using Jamar Hydraulic Hand Dynamometer to measure 
isometric force and peak strength with five adjustable grip positions. It has a 
consistently strong relationship to function, sarcopenia and frailty [10].   
• Visual analogue scores for pain: We will use the Numerical Rating Scale (NRS) [11] 
on the first and last treatment session. This is a 0-10 scale where respondents are 
asked to rate, for each leg, the current level of pain and the least, worst and 
average level of pain over the previous 24 hours.    
Outcome measures at 6 months after recruitment: 
• Barthel ADL score:  Designed to assess participants’ dependency, it is a 10 item 
questionnaire of personal ADL [12].  Research staff will collect the personal ADL by 
telephone or by post if necessary. 
• Nottingham Extended ADL: designed to assess participants dependency, is a 22 
item questionnaire of functional mobility, household and social activity [13].  
Research staff will collect the instrumental ADL by telephone or by post if 
necessary. 
• Length of hospital stay: from hospital records. 
• Readmission rate: from hospital records. 
• Discharge destinations: from hospital records. 
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These interventions will be provided additional to participants’ optimised care. A separate 
protocol for each intervention will be provided at the appendices section: 
Neuromuscular electrical stimulation  
Before the NMES application, warming exercises will be performed on the lower extremity 
muscles for 5 minutes. The variant of neuromuscular electrical stimulation we will test 
involves a small electric current applied via a skin electrode overlying the nerves supplying 
the muscles of the leg while the patient is lying in bed, positioned in supine with the knee 
in full extension. Quadriceps will be stimulated on the sound leg for 30 min, 3 days per 
week for 6 weeks or until discharged from hospital. Treatment is adjusted to generate a 
specific force and maintained for up to 5 minutes, followed by a rest period and then 
repeated three times over the typical 30-minute session. The stimulation can vary 
according to the frequency (pulses per second, typically 10-50Hz).  In this study, we will 
stimulate one of the participants’ legs, using the other leg as a control comparison.  
Additional protein supplementation: high protein supplementation (ONS). 
We will randomly allocate participants offering half of them additional protein 
supplementation over and above their ordinary diet. In this way, we will be able to observe 
the effect at the muscle level of neuromuscular stimulation (a comparison between legs), 
and its effect with and without additional protein supplementation (on a randomised 
basis). Evidence from many sources indicated that 20g protein after a bout of exercise is 
the maximum amount that can possible be metabolized [10]. A standard (100g) portion of 
ONS gives 20g protein. 
Data analysis 
Between group statistical testing will employ simple parametric (t-test, either on raw or 
transformed data) or non-parametric (Mann-Whitney) tests as determined by the sample 
distributions of the outcome measures. Intention to treat and on-treatment analyses will 
be performed. Interaction effects will be examined with bilateral pre/post parameters. 
Secondary post-hoc, data driven analyses will also be conducted as required. Simple 
descriptive statistics will be used for all other analyses. Reasons for missing data will be 
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The anonymised dataset will be available on request to the PI for further analysis and 
comparison with other datasets. 
 
Public and patient involvement 
Two of the named investigators represent patient and public involvement in this study. 
They represent and consult with a larger, autonomous, PPI group, and both have 
considerable and varied expertise as PPI contributors to research. They have contributed 
to the overall research programme in which this study is nested. They have contributed to 
this protocol by requesting clarification and details of importance, particularly but not 
solely, related to the lay reader and patient. 
 
Data management 
Data management plan will be in line with the Nottingham University research data 
management policy (https://uniofnottm.sharepoint.com/sites/DMPCollection). 
 
Ethical Approval 
The protocol was approved by the East Midlands – Nottingham 2 Research Ethics Committee 




Our belief is that interventions sufficient to make a meaningful impact on independence 
and wellbeing after a fragility fracture will need to be multimodal. In frailty states the 
deficits and hence problems are multiple and it follows that multiple interventions will be 
required, on an individualised basis, to address a sufficient number of to alter outcome. 
The core of such an intervention package would include best existing care, including 
optimising resistance exercise and nutrition, but an enhanced package would include novel 
interventions such as neuromuscular electrical stimulation (NMES), whole body vibration 
therapy or anabolic drugs. Each intervention component needs to be demonstrated to be 
feasible in the population of interest before applied in a novel intervention package. We 
hope that this study will determine whether NMES is suitable to be used in such a novel 
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interventions in this study group and setting, before their synthesis in a novel multimodal 
package. Whilst the final trial of a multimodal intervention package will require meaningful 
clinical outcomes such as survival, independence, and mobility, we believe that potential 
candidate components need to demonstrate feasibility, acceptability, and efficacy at the 
biological level (such as improved muscle strength).     
 
We acknowledge that this study will not be able to determine whether NMES improves 
clinical outcomes - partly because we will only stimulate one leg here yet obviously 
bilateral stimulation would be more suitable to optimise functional gains. We have chosen 
this method to determine whether NMES as we can deliver it will mimic the benefits seen 
in other uses of the technique at the muscular level. We acknowledge that further 
feasibility and acceptability research will be required when multimodal clinical treatment 
packages are developed further along the research pathway. We also acknowledge that 
this study will not examine the long-term community use of NMES, and further work will 
be necessary to do this since NMES could be an adjunct to rehabilitation in both the 
hospital and community phases. 
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